Tools chosen: kalshi_direct claude_news gdelt_news kalshi_related polymarket_related wikipedia

Sub-questions (Fermi decomposition)

Planner reasoning

This is a policy-action question about whether Trump eliminates the cost of at least one IVF cycle before Jan 20, 2029. The Kalshi market price is the primary anchor, and recent news on Trump's IVF executive orders and announcements is critical since he has made public statements about making IVF free.

# Current state The resolution criterion requires the President to take an action that **eliminates the cost** of at least one IVF cycle before Jan 20, 2029. As of mid-2026, the administration has taken incremental steps (EO, drug discounts, voluntary employer benefit framework) but has explicitly abandoned the insurance mandate and has no legislative vehicle in Congress. IVF remains ~$12,000–$25,000 per cycle out-of-pocket. # Timeline of key events - **2025-02-18** — Trump signs EO 14216 "Expanding Access to IVF"; no funding, no mandate, no new rights created [WhiteHouse.gov, confirmed] - **2025-08-03** — WaPo reports White House has internally abandoned plan to require insurers to cover IVF [WaPo, confirmed/reported] - **2025-10-16** — Trump announces drug discount deal with EMD Serono (84% off Gonal-f, Ovidrel, Cetrotide via TrumpRx.gov, starting Jan 2026); saves ~$2,200/cycle on meds only [Prelude Fertility, confirmed] - **2026-05-13** — Proposed rule published in Federal Register establishing "Excepted Fertility Benefits" category — voluntary employer HRA-style benefit, capped ~$2,150/year; comment period closes July 13, 2026 [Federal Register, confirmed] --- # Event Will Trump take action eliminating the cost of at least one IVF cycle before January 20, 2029? # Outcomes to forecast - **Yes** — President takes action eliminating cost of ≥1 IVF cycle before Jan 20, 2029 - **No** — No such action taken # Kalshi market anchor **KXFREEIVF-29: 14% YES** | 7-day change: 0% | 30-day change: 0% | Avg daily volume: 40 contracts | Range (59 days): 12–17%. Market is stable and low-conviction on Yes. # Sub-question answers 1. **Has Trump signed any EO eliminating/covering IVF cost?** — No. EO 14216 (Feb 18, 2025) expands stated policy support but creates no coverage mandate, new rights, or funding mechanism. [WhiteHouse.gov, KFF] 2. **Status of Feb 2025 EO and follow-up actions?** — EO remains in force but produced only: (a) a voluntary drug discount program via TrumpRx.gov (84% off select meds, ~$2,200 savings), and (b) a proposed "Excepted Fertility Benefits" rule (voluntary employer HRAs, ~$2,150 cap). No mandate. [Prelude Fertility, Federal Register, DOL] 3. **Does President have unilateral authority to make IVF free?** — No. Mandating insurer coverage or creating a federal subsidy program requires Congressional action/appropriations. Executive orders bind only the federal executive branch. [Wikipedia/EO article, KFF, Segal] 4. **What have officials said about timeline/mechanism?** — WaPo (Aug 2025) reports White House has *no plan* to mandate insurer coverage despite campaign pledge. Drug discounts and voluntary employer frameworks are the ceiling of current ambition. [WaPo] 5. **Are insurance-mandate or federal-coverage proposals being implemented?** — No. The May 2026 proposed rule creates a *voluntary* employer benefit category (not a mandate) capped far below actual cycle costs. No qualifying action under resolution criteria. [Federal Register, ASRM] # Key facts (high-confidence, factual) 1. [KFF] Legislation is required to mandate IVF coverage for private/self-funded plans; no such bill is moving in Congress. 2. [WaPo, Aug 2025] White House explicitly abandoned insurer mandate plan. 3. [ASRM] Drug discount saves ~$2,200/cycle on a subset of drugs; full IVF cycle costs $12,000–$25,000+. 4. [Federal Register, May 2026] Proposed "Excepted Fertility Benefits" rule is voluntary, ~$2,150 annual cap — far below cycle cost; still in comment period. 5. [Segal, KFF] 2024 Senate bills mandating IVF coverage failed with near-unanimous Republican opposition. 6. [Wikipedia] Executive orders bind only federal executive branch; cannot compel private insurers without statutory authority. # Cross-market signals - **Kalshi related:** No other directly comparable IVF market. Trump "bring back manufacturing" (17%) and "govt spending cuts ≥$250B" (15%) suggest market places ~14–17% on ambitious Trump second-term pledges being fulfilled — consistent with IVF anchor. - **Polymarket:** No active IVF market found. - **Sportsbook:** N/A. # Analyst opinions and speculation - ASRM: "True equity demands mandatory insurance coverage" — current steps are insufficient. [ASRM] - KFF: Employer incentive framework requires Congress; administration has not pursued that path. [KFF] - No credible analyst or publication anticipates full cost elimination before 2029. # Directional lean per outcome - **Yes (14%):** Supporting — Trump has political motivation; IVF is a popular bipartisan issue; remaining ~2.5 years for action. Opposing — WaPo confirms mandate abandoned; no legislative path; voluntary measures structurally insufficient; resolution requires *eliminating* cost, not reducing it. - **No (86%):** Strong structural, political, and legal barriers; administration has signaled retreat from mandate; Congress would need to act; cycle costs remain ~$12K–$25K. # Gaps / unknowns - Whether final "Excepted Fertility Benefits" rule (post-July 2026 comment) could be interpreted as eliminating cost (very unlikely given $2,150 cap). - Any future surprise legislative deal (e.g., budget reconciliation add-on) — currently no signal. - Whether military/federal employee IVF coverage expansion could satisfy resolution criteria (narrow population, not "free IVF" broadly). # Calibration anchors - **Kalshi anchor: 14% YES** — stable, low-volume market; no movement in 30 days. - **Precedent:** Campaign pledges involving congressional action (IVF mandate) have a poor track record when Congress is resistant; 2024 Senate vote showed GOP opposition. Current admin actions are ~10–15% of what "free IVF" would require. **Fair value: ~10–14% Yes**, consistent with Kalshi.

1. Both forecasters treat "eliminating cost" as requiring a universal program, but the brief flags a narrow scenario neither adequately weighs: whether expanded military/federal employee IVF coverage could satisfy the resolution criterion for a specific population. This could represent a unilateral executive action within existing statutory authority, yet both forecasters essentially dismiss it in one clause. 2. Neither forecaster quantifies the remaining ~2.5-year window probabilistically against base rates for surprise legislative attachments (e.g., budget reconciliation riders). The brief notes 2024 Senate bills failed with near-unanimous GOP opposition, which is strong evidence, but neither forecaster explicitly uses that vote as a calibration anchor for the legislative path's probability. 3. Forecast 1 argues Kalshi's 14% "overweights a vague 'reduce cost' interpretation" and goes to 8%, but the brief explicitly states the resolution criterion is "eliminates cost"—so Kalshi traders are presumably already pricing the strict standard. This justification for going below the market anchor is circular and unsupported. 4. Both forecasters underweight the political incentive channel: IVF is broadly popular and Trump has historically surprised on transactional deals. The brief's cross-market signal notes ~14-17% for other "ambitious second-term pledges," yet neither forecaster engages with whether this reference class should push them toward or away from the Kalshi anchor. 5. Neither forecaster addresses the post-July 2026 comment period outcome for the "Excepted Fertility Benefits" rule—specifically whether a finalized, enhanced version could be structured to cover a full cycle for a narrow category of federal workers, which the brief identifies as a genuine gap/unknown rather than a closed question.

11% (50% confidence)

Yes: 11% No: 89%

Resolution requires eliminating the full cost of at least one IVF cycle. All current actions fall far short: EO with no mandate, drug discounts (~$2,200) and voluntary employer benefits (~$2,150 cap) versus $12K-$25K cycle costs. The mandate was abandoned and requires Congress, which showed near-unanimous GOP opposition in 2024. The critique fairly notes forecasters dismissed narrow federal/military coverage pathways and going below market (8%) was weakly justified, so I anchor near the stable Kalshi 14% but slightly below given the strict 'eliminate' standard.

Total pipeline time: 160.7s